CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 614 enrolled
Drug / intervention
QVA149 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01682863
NCT01682863Phase 3Completed
CompareCT.gov

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Novartis Pharmaceuticals·interventional·Posted Sep 11, 2012·Updated Mar 30, 2016

In Brief

A Phase 3 clinical trial evaluating QVA149, QAB149, and 1 other intervention for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 614 participants across 86 sites in 7 countries.

Detailed Summary

This study is to assess the safety and tolerability of two different doses of QVA149 and QAB149 in patients with moderate to severe airflow limitation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease (COPD)
CountriesBulgaria, Finland, Hungary, Puerto Rico, Romania, Spain, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 11, 2012
Enrollment StartOct 1, 2012
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 13.8 years ago

Interventions

QVA149drug

QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI

QVA149drug

QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI

QAB149drug

QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI

Placebodrug

To mimic QAB149